In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells.

@article{Frisch2009InVP,
  title={In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells.},
  author={Benjamin J. Frisch and Rebecca L. Porter and Benjamin J Gigliotti and Adam J. Olm-Shipman and Jonathan M Weber and Regis J O'keefe and Craig T. Jordan and Laura M Calvi},
  journal={Blood},
  year={2009},
  volume={114 19},
  pages={4054-63}
}
Microenvironmental signals can determine hematopoietic stem cell (HSC) fate choices both directly and through stimulation of niche cells. In the bone marrow, prostaglandin E(2) (PGE(2)) is known to affect both osteoblasts and osteoclasts, whereas in vitro it expands HSCs and affects differentiation of hematopoietic progenitors. We hypothesized that in vivo… CONTINUE READING